WASHINGTON, March 28, 2017 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, Inc. has joined the health policy research organization as its newest member. David Cox, PhD, Vice President, Medical and Regulatory Affairs (North America), will serve as his company's representative on NPC's Board of Directors.
"We're pleased to have Ipsen and Dr. Cox join NPC as members," said NPC President Dan Leonard. "We welcome their insights in helping us identify and address health care priorities in today's rapidly changing policy environment."
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen, a global specialty-driven pharmaceutical group focused on discovering, developing and commercializing new therapeutic options for oncologic, neurologic and endocrine diseases.
"At a time when all of us in health care are facing a number of challenges, we appreciate NPC's thoughtful, research-oriented approach in considering how to improve health system efficiencies and lower access barriers to high-value care, among other issues," said Dr. Cox. "We're looking forward to engaging with NPC on these important health care matters."
About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.
About Ipsen in North America
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen, a global specialty-driven pharmaceutical group. The U.S. head office is located in Basking Ridge, New Jersey. Ipsen Biopharmaceuticals Canada, Inc. is an integrated business unit within North America and has its head office located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen U.S. research and development center focused on peptide research in oncology and endocrinology, is located in Cambridge, Massachusetts. At Ipsen Bioscience, we focus on creating a highly cooperative and passionate R&D organization through partnerships, innovation, and continuous learning to effectively deliver new treatments for patients. At Ipsen, we focus our resources, investments, and energy on discovering, developing, and commercializing new therapeutic options for oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
SOURCE National Pharmaceutical Council